- In the News
- Welcome to PDSA
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
"Abstract: In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet counts after discontinuing romiplostim. Here, we examined rates of platelet response (≥50 × 109 /l), remission, splenectomy and adverse events in patients with primary ITP duration ≤6 months who were treated with romiplostim for ≤12 months. The starting dose of romiplostim was 1 μg/kg; concomitant and rescue treatments were permitted to maintain platelet counts. Patients with platelet counts ≥50 × 109 /l at the end of 12 months entered a dose taper in which the romiplostim dose was decreased as long as platelet counts were maintained."
From the British Journal of Haematology
B cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy
"BACKGROUND:Immune thrombocytopenic purpura (ITP) is characterized by reduced platelet count secondary to immune-mediated destruction, this results into an increased bleeding risk. Auto-antibodies binding to platelets tag them for premature destruction in the spleen. For this reason splenectomy is often performed as treatment of chronic forms of disease that are resistant to pharmacological therapy."
- By Paola Giordano et al., published in Pediatric Research (2015)
'I thought my son was going to bleed to death': Medicine gives hope for Manchester child with rare blood disorder
“'It’s devastating. I thought my son was going to bleed to death, and it just doesn’t stop. At one point the bleeding was even longer than eight hours.' Eight-year-old George May from Royton lives in ‘fear of everything’ as one small knock can leave him bleeding for hours until getting treated at the hospital. Diagnosed at the age of four with immune thrombocytopenia (ITP), George has a rare bleeding disorder which stops his blood from clotting as it should."
- By Jessica Beard, Mancunian Matters
"Making the world of ITP a more manageable place to be"
The Platelet Disorder Support Association is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through:
Education • Advocacy • Research • Support
Comprehensive information on conventional therapies usually prescribed for ITP as well as therapies outside of the usual medical mainstream that some patients with ITP have used successfully.
Advocacy helps build awareness and support for ITP and other platelet disorders. Everyone interested in having more people know about ITP, having greater access to treatment, and getting more funding ITP and related diseases can help.
ITP Conference DVDs, free booklets and pamphlets, diet and lifestyle information, PDSA newsletters, journal articles and abstracts, PDSA E-News.